CBD Guide: What the Research Actually Shows

Cannabidiol has moved from obscurity to supermarket shelves in under a decade, and the volume of claims made about it has grown considerably faster than the evidence behind them. This guide sets out what CBD is, how it behaves in the body, what research has and has not established, and what to check before buying. Each section links through to our reporting on that subject.

CBD Health & Wellness has covered cannabinoid science, regulation and product development since 2018. Where the evidence is genuinely promising, we say so. Where it is preliminary, confined to laboratory models, or contested, we say that too.

At a glance

CBD is non-intoxicating, but it is pharmacologically active — that is not the same as inert.
Prescription CBD has demonstrated benefit for specific seizure disorders. Most other uses rest on substantially weaker evidence.
Oils, capsules, inhaled products and topicals differ considerably in absorption, onset and duration.
CBD can cause side effects and can interact with prescription medications.
Retail product quality varies. Labels and marketing claims should not be taken at face value.

What CBD is

Cannabidiol (CBD) is one of the major cannabinoids produced by Cannabis sativa, particularly in hemp and CBD-dominant varieties. How much of it a given plant contains depends heavily on its chemotype: CBD-rich cultivars are bred for it, while THC-dominant cannabis may contain very little.

CBD and THC are more closely related than most people realise. Both begin as cannabigerolic acid (CBGA). Different enzymes convert that precursor into cannabidiolic acid (CBDA) or tetrahydrocannabinolic acid (THCA), which then lose carbon dioxide through heat and, more gradually, time, to become CBD and THC. The resulting molecules share the same molecular formula but differ in structure, and those structural differences profoundly change how each interacts with the body.

THC produces intoxication largely by acting as a partial agonist at CB1 receptors in the brain. CBD has little direct activity at that receptor and does not produce the characteristic THC high — it is non-intoxicating.

How CBD works in the body

Humans produce their own cannabinoids. The endocannabinoid system — a network of receptors, signalling molecules and the enzymes that build and break them down — is involved in regulating sleep, appetite, pain signalling, mood and immune response. Plant cannabinoids are of interest largely because they interact with this existing system.

CBD’s mechanism is considerably less settled than THC’s, and several aspects remain unresolved. Rather than acting strongly at the main cannabinoid receptors, CBD appears to influence a number of targets. Reviews commonly discuss 5-HT1A serotonin signalling, transient receptor potential (TRP) channels, adenosine signalling, and indirect effects on the body’s own endocannabinoid tone. This multi-target, relatively low-affinity profile is part of why CBD’s effects are subtler and harder to study than THC’s.

CBD, THC and the wider cannabinoid family

CBD and THC are two of well over a hundred cannabinoids identified in cannabis. Several of the minor cannabinoids have attracted research interest in their own right — CBG, whose acidic precursor CBGA sits at a central branch point in cannabinoid biosynthesis; CBN, which forms as THC degrades with age and exposure; and CBC, among others. Most of this work remains preclinical, but it is where much of the genuinely interesting science now sits.

Isolate, broad spectrum and full spectrum

Three terms dominate product labelling, and they are commercial descriptions rather than strictly standardised scientific categories. Definitions vary between manufacturers.

CBD isolate — highly purified CBD with the other plant compounds removed. A properly manufactured isolate should contain no detectable THC.
Broad spectrum — contains a range of cannabinoids and other plant compounds, with THC intended to have been removed.
Full spectrum — retains a wider range of the plant’s cannabinoids and other compounds, and may contain trace THC. The term itself does not guarantee that a product complies with applicable law.

Worth distinguishing from all three: hemp seed oil is pressed from seeds and contains little or no cannabinoid content. It is a culinary and cosmetic oil, not a CBD product, and the two are frequently confused on labels and in listings.

The idea that whole-plant preparations may work differently from isolated CBD — often called the entourage effect — is plausible and widely discussed, but it remains an area of active investigation rather than settled fact.

How people take CBD

Delivery method changes almost everything about the experience — how much of the compound reaches the bloodstream, how quickly it takes effect, and how long it lasts. An oil held under the tongue behaves differently from a capsule swallowed, which behaves differently again from a cream applied to skin. Topicals are generally intended to act locally rather than throughout the body.

Oral CBD in particular is subject to extensive first-pass metabolism in the liver, meaning only a fraction of the labelled dose reaches circulation. Absorption also varies with whether it is taken with food.

How much CBD?

There is no universally established wellness dose for CBD. Doses used in clinical research vary widely and are often far higher than typical retail serving sizes. The approved epilepsy medication, for instance, is dosed by body weight under medical supervision.

A common source of confusion is the difference between the milligrams per serving and the total milligrams in the package. A bottle advertising 1,000 mg may deliver a small fraction of that per dose. Check the serving size, not the headline number.

How much CBD is right for you? Medical cannabis experts weigh in

What the research says

Prescription CBD is not the same as retail CBD

This distinction matters more than almost anything else on this page, and it is routinely blurred in marketing.

One use has crossed the full evidentiary and regulatory threshold: prescription purified CBD is approved in the United States for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex. That approval followed randomised controlled trials, and the product is manufactured to pharmaceutical standards, dosed by a clinician and taken under medical monitoring.

None of that can be assumed to transfer to a retail CBD oil. The differences span dose, purity, formulation, manufacturing controls, medical supervision and the evidence supporting use. Evidence for a prescription product in those specific seizure disorders is not evidence that retail CBD products treat epilepsy generally — or that CBD treats unrelated conditions.

Evidence at a glance

Subject	Where the evidence currently stands
Specific seizure disorders	Established for prescription purified CBD
Anxiety	Promising, but studies remain limited and varied
Sleep	Mixed; may depend on dose and underlying cause
Pain	Insufficient CBD-specific clinical evidence
Skin conditions	Early, largely preclinical
General wellness	Broad general-wellness claims lack direct clinical support
Pregnancy and breastfeeding	Avoid unless specifically directed by a clinician
Pets	Limited evidence; veterinary guidance advisable

Pain and recovery

CBD is heavily marketed for pain and recovery, but the clinical evidence for CBD alone is much thinner than the broader evidence for cannabis-based medicines, most of which contain THC. Laboratory research has identified several plausible inflammatory and pain-signalling pathways. Plausible mechanisms are not the same as demonstrated relief in patients.

Sleep

The relationship between CBD and sleep is less settled than the marketing implies — including the basic question of whether it is sedating at all, or whether reported improvements arrive indirectly through reduced discomfort or anxiety. Effects may depend on dose, timing, formulation and the underlying reason someone is sleeping poorly.

Anxiety, stress and mood

Anxiety is among the more promising areas of CBD research, but the studies remain small, varied in design and dose, and often short-term.

Skin

Work on cannabinoids in skin is genuinely interesting but mostly early and preclinical. Cosmetic marketing has run well ahead of it.

Other health conditions

Beyond the approved seizure indications, CBD has been investigated across a wide range of neurological, cardiovascular and inflammatory conditions. The maturity and quality of that evidence vary substantially, and much of it remains preliminary.

CBD is non-intoxicating, not risk-free

Because CBD does not produce a high, it is often assumed to be harmless. It is generally well tolerated, but it is an active compound with a recognised side-effect profile. Reported effects include:

Drowsiness and sedation
Diarrhoea and other gastrointestinal effects
Changes in appetite and weight
Elevations in liver enzymes, observed in clinical research including at higher doses
Additive sedation when combined with alcohol or other sedating substances

Severity varies with dose and formulation, and higher doses are more likely to produce effects than the small quantities in many consumer products.

Drug interactions

CBD is metabolised by the cytochrome P450 enzyme system, which also processes a large share of prescription medications. This creates genuine potential for interaction — CBD can alter the levels of other drugs in the body, and other drugs can alter CBD levels.

This is the single most important reason to speak to a doctor or pharmacist before combining CBD with existing prescriptions, particularly blood thinners, anti-epileptics, immunosuppressants and sedatives.

Pregnancy, breastfeeding and children

Because fetal and infant safety has not been established, health authorities advise avoiding CBD during pregnancy and breastfeeding. Contamination of unregulated products is an additional concern. CBD is expected to pass into breast milk, but the amount transferred and its effects on a nursing infant are not well established.

Prescription CBD is approved for certain seizure disorders in patients aged one year and older, but that does not make ordinary retail CBD products appropriate for children. CBD should not be given to a child without guidance from a qualified paediatric clinician.

Pets

Veterinary evidence remains limited, dosing is poorly standardised, and products intended for humans may contain THC, xylitol or other ingredients unsafe for animals — xylitol can cause severe and potentially fatal poisoning in dogs, and dogs are more sensitive to THC than people. Speak to a veterinarian first.

Product quality and how to read a certificate of analysis

Independent testing has repeatedly found retail products whose contents differ from their labels, in both directions, and some containing contaminants. A recent, batch-specific certificate of analysis (COA) from a credible independent laboratory is one of the best tools available for checking a product — though it is not an absolute guarantee, since a COA can be outdated, selective, drawn from a different batch, or difficult to authenticate.

What to look for:

Product and batch numbers that match the item in your hand
A recent test date
CBD and THC quantities, stated per unit as well as per package
Screening for pesticides, heavy metals, residual solvents and microbial contaminants
The identity and accreditation of the testing laboratory
The complete report, rather than only a potency summary

CBD test results: what to look for, what to look out for

Legal and regulatory status

Last reviewed: 29 July 2026. This section is focused on the United States. Rules change, and they differ by country and by state — check the date on anything you read about CBD law, including this page.

Federal CBD law in the United States involves two separate questions: whether the material qualifies as hemp under controlled-substance law, and whether the finished product may lawfully be marketed as a food, dietary supplement, drug or cosmetic. Conflating the two is the most common error in consumer explanations.

The hemp question. As of July 2026 the definition created by the 2018 Farm Bill remains in effect: hemp generally includes Cannabis sativa and its derivatives containing no more than 0.3% delta-9 THC on a dry-weight basis. That changes on 12 November 2026. A law enacted on 12 November 2025 (Public Law 119-37) replaces the delta-9-only threshold with a total-tetrahydrocannabinols standard that includes THCA. It also excludes finished hemp-derived cannabinoid products containing more than 0.4 mg per container, calculated as the combined total of THC-class cannabinoids and certain other cannabinoids determined to have, or marketed as having, THC-like effects. For this purpose, the container is the innermost retail packaging in direct contact with the product. The change is likely to affect a substantial number of full-spectrum products currently sold under the existing definition. Bills to delay implementation have been introduced in both chambers, but as of 29 July 2026 they remained at the introduced and committee-referral stage.

The FDA question. Separately, and regardless of hemp status, the FDA continues to maintain that CBD is excluded from the dietary-supplement definition — because it is an active ingredient in an approved drug and was also the subject of substantial, publicly known clinical investigations before being marketed as a supplement or conventional food. On the same basis, the agency’s position is that foods to which CBD has been added may not be introduced into interstate commerce. In 2023 it concluded that the existing food and supplement frameworks were not suitable for CBD and called on Congress to create a new regulatory pathway. That announcement did not itself create one.

The result is not simply an “unregulated” market. It is a market governed by overlapping federal and state rules, in which products are widely sold despite unresolved or contested compliance under federal food and supplement law. Federal enforcement has often prioritised unapproved disease claims and products considered especially risky — including CBD in foods and animal products, child-appealing formats, and items containing undeclared drugs — rather than attempting to remove the entire retail category at once.

Outside the US, rules vary substantially. Several jurisdictions regulate ingestible CBD under novel-food regimes, each with its own authorisation requirements, while topical and medicinal products may fall under different frameworks again.

Laws & Regulations

A note on what this page is not

Nothing here is medical advice. CBD is not a substitute for professional care. If you have a diagnosed condition, take prescription medication, are pregnant or breastfeeding, or are considering CBD for a child or animal, speak to a qualified clinician or veterinarian first.

Where to go next

Browse by subject through the CBD Basics, Using CBD, Cannabinoid Science, Health Conditions, Pain & Recovery, Mental Health, Sleep, Skin & Beauty, Women’s Health and CBD for Pets sections.

CBD: What the Research Actually Shows